Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20557981rdf:typepubmed:Citationlld:pubmed
pubmed-article:20557981lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:20557981lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:20557981lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:20557981lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:20557981lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:20557981lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:20557981lifeskim:mentionsumls-concept:C0205460lld:lifeskim
pubmed-article:20557981lifeskim:mentionsumls-concept:C0301869lld:lifeskim
pubmed-article:20557981pubmed:issue9lld:pubmed
pubmed-article:20557981pubmed:dateCreated2010-8-9lld:pubmed
pubmed-article:20557981pubmed:abstractTextA series of 3,5-diaryl-isoxazoline/isoxazole linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates were prepared. These conjugates showed potent anticancer activity with GI(50) values in the range of <0.1-3.6 microM. Some of these PBD conjugates (6a-c) with promising anticancer activity were further investigated on the cell cycle distribution. Moreover, these PBD conjugates exhibited G0/G1 arrest, enhancement in the levels of p53 protein as well as mitochondrial-mediated intrinsic pathway, leading to release of cytochrome c, activation of caspase-3, cleavage of PARP and subsequent apoptotic cell death. Hence these PBD conjugates with 6a being the most potent one could be be taken up for preclinical studies either alone or in combination with existing therapies.lld:pubmed
pubmed-article:20557981pubmed:languageenglld:pubmed
pubmed-article:20557981pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20557981pubmed:citationSubsetIMlld:pubmed
pubmed-article:20557981pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20557981pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20557981pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20557981pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20557981pubmed:statusMEDLINElld:pubmed
pubmed-article:20557981pubmed:monthSeplld:pubmed
pubmed-article:20557981pubmed:issn1768-3254lld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:KamalAhmedAlld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:SenSubrataSlld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:Pal-BhadraMan...lld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:BharathiE...lld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:JuvekarAartiAlld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:ZingdeSurekha...lld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:DastagiriDDlld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:SultanaFarhee...lld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:PushpavalliS...lld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:RamaiahM...lld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:ReddyJ...lld:pubmed
pubmed-article:20557981pubmed:authorpubmed-author:AzharM...lld:pubmed
pubmed-article:20557981pubmed:copyrightInfo2010 Elsevier Masson SAS. All rights reserved.lld:pubmed
pubmed-article:20557981pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20557981pubmed:volume45lld:pubmed
pubmed-article:20557981pubmed:ownerNLMlld:pubmed
pubmed-article:20557981pubmed:authorsCompleteYlld:pubmed
pubmed-article:20557981pubmed:pagination3924-37lld:pubmed
pubmed-article:20557981pubmed:meshHeadingpubmed-meshheading:20557981...lld:pubmed
pubmed-article:20557981pubmed:meshHeadingpubmed-meshheading:20557981...lld:pubmed
pubmed-article:20557981pubmed:meshHeadingpubmed-meshheading:20557981...lld:pubmed
pubmed-article:20557981pubmed:meshHeadingpubmed-meshheading:20557981...lld:pubmed
pubmed-article:20557981pubmed:meshHeadingpubmed-meshheading:20557981...lld:pubmed
pubmed-article:20557981pubmed:meshHeadingpubmed-meshheading:20557981...lld:pubmed
pubmed-article:20557981pubmed:meshHeadingpubmed-meshheading:20557981...lld:pubmed
pubmed-article:20557981pubmed:meshHeadingpubmed-meshheading:20557981...lld:pubmed
pubmed-article:20557981pubmed:meshHeadingpubmed-meshheading:20557981...lld:pubmed
pubmed-article:20557981pubmed:meshHeadingpubmed-meshheading:20557981...lld:pubmed
pubmed-article:20557981pubmed:meshHeadingpubmed-meshheading:20557981...lld:pubmed
pubmed-article:20557981pubmed:year2010lld:pubmed
pubmed-article:20557981pubmed:articleTitleDesign, synthesis and biological evaluation of 3,5-diaryl-isoxazoline/isoxazole-pyrrolobenzodiazepine conjugates as potential anticancer agents.lld:pubmed
pubmed-article:20557981pubmed:affiliationDivision of Organic Chemistry, Indian Institute of Chemical Technology, Tarnaka, Hyderabad 500 607, India. ahmedkamal@iict.res.inlld:pubmed
pubmed-article:20557981pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20557981pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:20557981lld:chembl